Fig. 4

Increased CD3−/CD56+ NK cells proliferation in peripheral blood of PV and ET patients treated with PegINFα. PBMC were collected from patients prior to and after at least 10 weeks of treatment and analyzed for surface markers CD3 and CD56 and intra-cellular marker Ki-67. a shows CD56+ frequency and b shows frequency of Ki-67+ CD56+ NK cells